Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277000 | 0.93 | SLC2A1 (0.67) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL11222662 | 0.93 | SLC2A1 (0.54) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL10388278 | 0.93 | SLC2A1 (0.54) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL16678877 | 0.93 | SLC2A1 (0.54) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL14500937 | 0.92 | SLC2A1 (0.52) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL16377619 | 0.92 | SLC2A1 (0.52) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL16330459 | 0.92 | SLC2A1 (0.52) | SLC2A1GBA1MAPK1GJB2TNF | |
| SCHEMBL6950601 | 0.88 | SLC2A1 (0.49) | SLC2A1GBA1MAPK1GJB2ADORA2A | |
| SCHEMBL8435866 | 0.88 | SLC2A1 (0.49) | SLC2A1GBA1MAPK1GJB2ADORA2A | |
| SCHEMBL16678933 | 0.88 | SLC2A1 (0.56) | SLC2A1GBA1MAPK1GJB2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149489-B2 | Inhibitors of glycolysis useful in the treatment of brain tumors | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-06 | — | — | US | disclosed |
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | PDK2, G6PD, PCK2 | SLC2A1 45/4885GBA1 380/4885MAPK1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.